Want to see RVTY full AI Analyst Report?
RVTY Stock Chart & Stats
$93.96
-$0.88(-0.75%)
At close: 4:00 PM EST
$93.96
-$0.88(-0.75%)
Day’s Range― - ―
52-Week Range$81.22 - $118.30
Previous CloseN/A
Volume176.09K
Average Volume (3M)1.48M
Market Cap
$12.41B
Enterprise Value$13.40B
Total Cash (Recent Filing)$860.32M
Total Debt (Recent Filing)$3.35B
Price to Earnings (P/E)53.1
Beta0.96
Next Earnings
Aug 03, 2026EPS Estimate
1.21Next Dividend Ex-DateN/A
Dividend Yield0.29%
Share Statistics
EPS (TTM)2.10
Shares Outstanding111,559,780
10 Day Avg. Volume1,249,489
30 Day Avg. Volume1,476,830
Financial Highlights & Ratios
PEG Ratio-3.41
Price to Book (P/B)1.52
Price to Sales (P/S)3.85
P/FCF Ratio21.63
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue4.62
Enterprise Value/Gross Profit8.98
Enterprise Value/Ebitda17.34
Forecast
1Y Price Target
$106.88Price Target Upside13.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)5.25
Revenue Forecast (FY)$2.83B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables & Installed BaseRevvity’s business model pairs upfront instrument sales with repeat consumables, reagents and service contracts tied to an installed base. That creates durable recurring revenues, higher lifetime customer value and predictable annuity-like cash flows that support margins and long-term reinvestment.
Strong Absolute Cash GenerationRevvity produces substantial free cash flow in absolute terms, providing internal funding for capex, R&D, M&A and opportunistic buybacks. Persistently positive FCF supports balance-sheet flexibility and strategic initiatives, helping the company execute portfolio optimization and return capital over multiple years.
Fast-growing Software/ARR MixRapid SaaS and informatics ARR growth shifts revenue toward higher-margin, recurring streams and improves revenue visibility over time. Expanding software offerings and AI-enabled workflows create differentiation, sticky customer relationships, and scalable revenue that can materially lift margins and reduce cyclicality.
Bears Say
Low Returns & Earnings VolatilityRevvity’s low ROE and prior annual loss indicate the business currently generates modest returns on a large equity base. Persistent return compression and earnings volatility undermine capital efficiency, limit long-term shareholder return potential and complicate allocation decisions for growth versus capital returns.
China Immunodiagnostics Divestiture RiskSelling the China immunodiagnostics unit reduces scale and creates execution, timing and regulatory risks until close. The divestiture lowers near-term EPS and delays cash proceeds to 2027, creating a multi-quarter gap between operational impacts and financial benefits that can pressure near-term growth metrics.
Software Cadence And Visibility VolatilityWhile software is a strategic growth engine, management’s forecast of uneven quarterly SaaS performance reduces revenue predictability and complicates margin planning. Cadence volatility in recurring revenue makes forecasting and resource allocation harder and could blunt the steadier margin uplift expected from software over time.
Revvity News
RVTY FAQ
What was Revvity, Inc.’s price range in the past 12 months?
Revvity, Inc. lowest stock price was $81.22 and its highest was $118.30 in the past 12 months.
What is Revvity, Inc.’s market cap?
Revvity, Inc.’s market cap is $12.41B.
When is Revvity, Inc.’s upcoming earnings report date?
Revvity, Inc.’s upcoming earnings report date is Aug 03, 2026 which is in 32 days.
How were Revvity, Inc.’s earnings last quarter?
Revvity, Inc. released its earnings results on May 05, 2026. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.016 by $0.024.
Is Revvity, Inc. overvalued?
According to Wall Street analysts Revvity, Inc.’s price is currently Undervalued.
Does Revvity, Inc. pay dividends?
Revvity, Inc. pays a Quarterly dividend of $0.07 which represents an annual dividend yield of 0.29%. See more information on Revvity, Inc. dividends here
What is Revvity, Inc.’s EPS estimate?
Revvity, Inc.’s EPS estimate is 1.21.
How many shares outstanding does Revvity, Inc. have?
Revvity, Inc. has 111,559,780 shares outstanding.
What happened to Revvity, Inc.’s price movement after its last earnings report?
Revvity, Inc. reported an EPS of $1.04 in its last earnings report, beating expectations of $1.016. Following the earnings report the stock price went up 6.693%.
Which hedge fund is a major shareholder of Revvity, Inc.?
Currently, no hedge funds are holding shares in RVTY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Revvity Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$106.88 (13.75% Upside)
$106.88 (13.75% Upside)
Blogger Sentiment
Bullish
RVTY Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 76.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.36%
12-Months-Change
Fundamentals
Return on Equity
3.28%
Trailing 12-Months
Asset Growth
-2.95%
Trailing 12-Months
Company Description
Revvity, Inc.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
RVTY Company Deck
RVTY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive tone driven by a better-than-expected Q1 (organic growth, margin and EPS beats), strong cash conversion, healthy software ARR trends, and a strategic decision to divest a underperforming China diagnostics business that should improve longer-term margins and growth. Near-term cautions include China market weakness, Q2 software cadence volatility, a ~$0.15 EPS headwind in 2026 from the divestiture (with proceeds not realized until 2027), and reduced FX tailwinds. Management emphasized operational cost initiatives and expected margin expansion into the second half of the year and into 2027, supporting an upbeat long-term outlook despite the identified near-term risks.View all RVTY earnings summariesRVTY Revenue Breakdown
50.11% Life sciences
49.89% Diagnostics
RVTY Stock 12 Month Forecast
Average Price Target
$106.88
▲(13.75% Upside)
Technical Analysis
Ownership Overview
0.46% Insiders
55.66% Mutual Funds
5.02% Other Institutional Investors
12.63% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---